Skip to main content
. 2016 Sep 30;7(44):71790–71801. doi: 10.18632/oncotarget.12374

Figure 4. JWA mediates lapatinib resistance by negatively regulating HER2.

Figure 4

(A) SGC-7901 cells were transfected with JWA siRNA or 48 h, followed by exposure to 30 μM lapatinib for 24 h. The apoptotic rate was determined by the TUNEL assay (×1000). (B) Quantification of TUNEL-positive SGC-7901 cells transfected with JWA siRNA. (C) SGC-7901 cells were treated with lapatinib as in (A) and whole-cell lysates were collected for detection of target proteins by Western blotting. (D) NCI-N87 cells were transfected with Flag-JWA and then treated with 1μM lapatinib for 24 h. The apoptotic rate was determined by the TUNEL assay (× 1000). (E) Quantification of TUNEL-positive NCI-N87 cells transfected with Flag-JWA. Columns indicate average of triplicates and bars indicate SD. *P < 0.05, ***P < 0.001. (F) NCI-N87 cells were treated with lapatinib as in (D) and whole-cell lysates were collected for detection of target proteins by Western blotting. (G) Effects of lapatinib on downstream regulatory molecules of HER2. NCI-N87 cells with or without JWA overexpression were cultured in the presence or absence of lapatinib (1 μM, 24 h). Whole-cell lysates were collected for detection of target proteins by Western blotting.